131 related articles for article (PubMed ID: 1777219)
1. Hormone receptors as prognostic factors in female breast cancer.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
Ann Med; 1991 Dec; 23(6):643-8. PubMed ID: 1777219
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
Anticancer Res; 1991; 11(5):1701-6. PubMed ID: 1768039
[TBL] [Abstract][Full Text] [Related]
3. Comparison of classic and quantitative prognostic factors in hormone receptor-positive and hormone receptor-negative female breast cancer.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
Am J Surg; 1993 Mar; 165(3):307-11. PubMed ID: 8447534
[TBL] [Abstract][Full Text] [Related]
4. Histological assessment of the prognostic factors in female breast cancer.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Mari S; Alhava E; Syrjänen K
Oncology; 1992; 49(1):1-8. PubMed ID: 1542486
[TBL] [Abstract][Full Text] [Related]
5. Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer.
Lipponen P; Eskelinen M; Papinaho S; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
Anticancer Res; 1992; 12(3):677-82. PubMed ID: 1622125
[TBL] [Abstract][Full Text] [Related]
6. Hormone receptor measurements and survival in 1335 consecutive patients with primary invasive breast carcinoma.
Raabe NK; Hagen S; Haug E; Fossaa SD
Int J Oncol; 1998 May; 12(5):1091-6. PubMed ID: 9538134
[TBL] [Abstract][Full Text] [Related]
7. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
8. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
[TBL] [Abstract][Full Text] [Related]
9. DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer.
Eskelinen M; Lipponen P; Papinaho S; Aaltomaa S; Kosma VM; Klemi P; Syrjänen K
Int J Cancer; 1992 Jun; 51(4):555-61. PubMed ID: 1601520
[TBL] [Abstract][Full Text] [Related]
10. Prognostic scores combining clinical, histological and morphometric variables in assessment of the disease outcome in female breast cancer.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
Int J Cancer; 1991 Dec; 49(6):886-92. PubMed ID: 1959993
[TBL] [Abstract][Full Text] [Related]
11. Steroid receptors and prognosis in operable (stage I and II) breast cancer.
Stewart JF; Rubens RD; Millis RR; King RJ; Hayward JL
Eur J Cancer Clin Oncol; 1983 Oct; 19(10):1381-7. PubMed ID: 6315442
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer--results of the analysis of 670 patients with 11 years of follow-up.
Costa SD; Lange S; Klinga K; Merkle E; Kaufmann M
Eur J Cancer; 2002 Jul; 38(10):1329-34. PubMed ID: 12091062
[TBL] [Abstract][Full Text] [Related]
13. Mitotic indexes as prognostic predictors in female breast cancer.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
J Cancer Res Clin Oncol; 1992; 118(1):75-81. PubMed ID: 1729263
[TBL] [Abstract][Full Text] [Related]
14. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
15. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
[TBL] [Abstract][Full Text] [Related]
16. The oestrogen-progesterone receptor ratio: an indicator of breast cancer evolution.
Cherubini M; Baxa P; Guarino G
Chir Ital; 2002; 54(4):423-8. PubMed ID: 12239750
[TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer.
Lipponen P; Saarelainen E; Ji H; Aaltomaa S; Syrjänen K
J Pathol; 1994 Oct; 174(2):101-9. PubMed ID: 7965405
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH
J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
20. Estrogen and progesterone receptors in breast cancer: relationships to tumour histopathology and survival of patients.
Blanco G; Alavaikko M; Ojala A; Collan Y; Heikkinen M; Hietanen T; Aine R; Taskinen PJ
Anticancer Res; 1984; 4(6):383-9. PubMed ID: 6097159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
